News | August 06, 2009

Palatin Technologies Receives U.S. Patent Allowance for Heart Failure Drug Candidate

August 6, 2009 – Palatin Technologies Inc. said this week it received a notice of allowance from the U.S. Patent and Trademark Office covering a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, which is Palatin's lead heart failure drug candidate.

Patent application number 11/694,260, is titled "Cyclic Natriuretic Peptide Constructs." Palatin expects the patent will issue in the second half of 2009 and its 20-year term would expire in 2027.

"We are extremely pleased to be getting this patent coverage," said Palatin President and CEO Carl Spana. "PL-3994 and related compounds are first-in-class peptide mimetics with extended half-lives and favorable pharmacokinetic properties. These are the only drugs we are aware of that bind to NPRA and are suitable for subcutaneous administration, with the possibility of once-daily administration."

PL-3994 and the related family of cyclic compounds were discovered entirely in-house and are owned by Palatin. In addition to the allowed U.S. patent application, Palatin has applications pending in selected countries outside the United States and additional U.S. applications covering related compounds.

Palatin has completed two clinical trials with PL-3994, a phase 1 trial in healthy volunteers and a phase 2a trial in patients with controlled hypertension. PL-3994 produced dose-related decreases in blood pressure, increases in plasma cGMP (cyclic guanosine monophosphate), a natural messenger nucleotide, and increases in urine volume and sodium excretion. There were no serious or severe adverse events, the company said.

PL-3994 incorporates a new and proprietary amino acid mimetic developed by scientists at Palatin. PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug candidate with improved pharmacokinetic and pharmacodynamic properties.

For more information: www.palatin.com

Related Content

News | Pharmaceuticals

January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...

Home January 05, 2022
Home
News | Pharmaceuticals

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first small ...

Home January 04, 2022
Home
News | Pharmaceuticals

December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...

Home December 16, 2021
Home
Videos | Pharmaceuticals

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at ...

Home November 22, 2021
Home
News | Pharmaceuticals

November 19, 2021 — Results from two early clinical studies show the first version of an oral PCSK9-inhibitor ...

Home November 19, 2021
Home
News | Pharmaceuticals

November 15, 2021 — Esperion announced the presentation of three abstracts highlighting Nexletol tablets at the American ...

Home November 15, 2021
Home
News | Pharmaceuticals

November 15, 2021 — Novartis announced results from a pooled post-hoc analysis of Phase III ORION-9, -10 and -11 trials ...

Home November 15, 2021
Home
Feature | Pharmaceuticals | By Dave Fornell, DAIC Editor

There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart ...

Home October 13, 2021
Home
News | Pharmaceuticals

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

Home October 07, 2021
Home
News | Pharmaceuticals

May 15, 2021 — A new analysis of the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in ...

Home May 15, 2021
Home
Subscribe Now